2016年《美国内分泌医师协会与美国内分泌协会绝经后骨质疏松症诊疗指南》解读

Interpretation of American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2016

随着人口老龄化,骨质疏松症的患病率明显升高。骨质疏松症可导致患者身体功能受损、生活质量下降,其导致的骨折可显著增加患者的致残率和病死率,并带来极大的家庭和社会经济负担。有效的抗骨质疏松症治疗可显著降低骨质疏松性骨折的发生,对已发生骨折的患者也可有效避免再次发生骨折。2016年,美国内分泌医师协会(AACE)和美国内分泌协会(ACE)联合发布了更新的绝经后骨质疏松症诊疗指南。本文从骨折风险评估与骨质疏松症诊断、基础干预措施、药物干预方面对该指南进行解读,展现骨质疏松症诊治的新进展,提高临床实践水平。

The prevalence of osteoporosis is growing rapidly with the aging of the population. Osteoporosis leads to decrease of physical function and quality of life. Moreover,fracture due to osteoporosis can bring about increased disability rate and mortality,and a great burden on family and society. Thankfully,anti- osteoporotic treatment is able to decrease fractures,and subsequent fractures effectively among those who already suffer from fractures. From the aspects of fracture risk assessment and osteoporosis diagnosis, basic intervention and pharmacological intervention, this article briefly interpreted the updated Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis jointly issued by American Association of Clinical Endocrinologists（ AACE） and American College of Endocrinology（ ACE） in 2016, aiming to keep clinicians informed of the recent developments in osteoporosis diagnosis and treatment by which their clinical practice can be improved.